Evidence map›Paper›PMID 41993609›Full record

ArticleTheranostics2026

Phase I dose-escalation study of [¹⁷⁷Lu]Lu-LNC1011, a long-circulating dansyl-modified PSMA theranostics, in metastatic castration-resistant prostate cancer.

Jiarou Wang, Rongxi Wang, Jialin Xiang, Hongzhang Yang, Tianzhi Zhao, Feng Guo, Yingkui Liang, Zhaohui Zhu, Jingjing Zhang

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiarou WangDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College; State Key Laboratory of Complex Severe and Rare Diseases, Beijing; Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.
Rongxi WangDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College; State Key Laboratory of Complex Severe and Rare Diseases, Beijing; Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.
Jialin XiangDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College; State Key Laboratory of Complex Severe and Rare Diseases, Beijing; Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.
Hongzhang YangDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore.
Tianzhi ZhaoDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore.
Feng GuoDepartment of Nuclear Medicine, The Sixth Medical Center of PLA General Hospital, Beijing, 100048, China.
Yingkui LiangDepartment of Nuclear Medicine, The Sixth Medical Center of PLA General Hospital, Beijing, 100048, China.
Zhaohui ZhuDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College; State Key Laboratory of Complex Severe and Rare Diseases, Beijing; Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.
Jingjing ZhangDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: [ Methods: This open-label, non-randomized, Phase I dose-escalation trial enrolled mCRPC patients with PSMA-positive lesions confirmed by PSMA PET/CT. A total of nine patients received [ Results: During the dose-limiting toxicity (DLT) observation period, no DLTs occurred in any activity group. The cumulative absorbed dose to organs increased with the injected activity. The effective dose to the whole body was 1.30E-01 ± 1.91E-02 mSv/MBq. The kidneys received the highest radiation dose (3.33 ± 1.09 Gy/GBq), consistent with the expected biodistribution of PSMA-targeted ligands. For salivary glands and red bone marrow, the absorbed doses were 1.70 ± 1.04 Gy/GBq and 0.11 ± 0.03 Gy/GBq, respectively. The mean absorbed dose to tumors was 12.29 ± 6.50 Gy/GBq. The effective half-life of [ Conclusion: [

Indexed as

Antigens, SurfaceLutetiumProstatic Neoplasms, Castration-ResistantRadioisotopesRadiopharmaceuticalsAgedDipeptidesGlutamate Carboxypeptidase IIHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyProstate-Specific AntigenTheranostic NanomedicineTreatment OutcomeAntigens, SurfaceDipeptidesFOLH1 protein, humanGlutamate Carboxypeptidase IILutetiumLutetium-177Prostate-Specific AntigenRadioisotopesRadiopharmaceuticals[177Lu]Lu-LNC1011Dansyl-Modified PSMADosimetrymCRPCPhase IPSMARadiopharmaceutical therapy

Identifiers

PMID41993609
PMCPMC13080328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.